NYSE:HAE - Haemonetics Stock Price, Forecast & News

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Haemonetics declared that its board has initiated a stock buyback plan on Tuesday, February 6th 2018, which allows the company to buyback $260,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company's board believes its shares are undervalued.

Haemonetics Co. (NYSE:HAE) issued its quarterly earnings results on Friday, November, 1st. The medical instruments supplier reported $0.87 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.72 by $0.15. The medical instruments supplier earned $252.57 million during the quarter, compared to analyst estimates of $249.77 million. Haemonetics had a net margin of 6.90% and a return on equity of 24.59%. View Haemonetics' Earnings History.

Haemonetics is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Haemonetics.

Haemonetics will be holding an earnings conference call on Tuesday, February 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Haemonetics issued an update on its FY20 earnings guidance on Friday, November, 1st. The company provided earnings per share (EPS) guidance of $3.10-3.20 for the period, compared to the Thomson Reuters consensus estimate of $3.09. The company issued revenue guidance of +3-5% yr/yr to ~$996.6 million to $1.02 billion, compared to the consensus revenue estimate of $1.01 billion.

6 Wall Street analysts have issued 1-year price objectives for Haemonetics' shares. Their forecasts range from $138.00 to $148.00. On average, they expect Haemonetics' share price to reach $142.83 in the next twelve months. This suggests a possible upside of 32.9% from the stock's current price. View Analyst Price Targets for Haemonetics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Haemonetics.

Media headlines about HAE stock have been trending extremely negative on Sunday, according to InfoTrie. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Haemonetics earned a daily sentiment score of -4.5 on InfoTrie's scale. They also assigned news articles about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Haemonetics.

Some companies that are related to Haemonetics include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Antares Pharma (ATRS), Anika Therapeutics (ANIK), Cerus (CERS), OraSure Technologies (OSUR) and Meridian Bioscience (VIVO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include Endologix (ELGX), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Apache (APA), Zoetis (ZTS), NVIDIA (NVDA), Pfizer (PFE), Micron Technology (MU), Nexstar Media Group (NXST) and Citigroup (C).

Haemonetics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Boston Trust Walden Corp (0.24%), Columbus Circle Investors (0.24%), New York State Teachers Retirement System (0.17%), Assenagon Asset Management S.A. (0.06%), State of Michigan Retirement System (0.03%) and Louisiana State Employees Retirement System (0.02%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View Institutional Ownership Trends for Haemonetics.

HAE stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Nisa Investment Advisors LLC, State of Alaska Department of Revenue, New York State Teachers Retirement System, Campbell & CO Investment Adviser LLC and Cardinal Capital Management. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Michelle L Basil, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View Insider Buying and Selling for Haemonetics.

HAE stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Columbus Circle Investors, Boston Trust Walden Corp, Eqis Capital Management Inc., Sciencast Management LP, HBW Advisory Services LLC, State of Michigan Retirement System and Louisiana State Employees Retirement System. View Insider Buying and Selling for Haemonetics.

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HAE stock can currently be purchased for approximately $107.45.

Haemonetics has a market capitalization of $5.45 billion and generates $967.58 million in revenue each year. The medical instruments supplier earns $55.02 million in net income (profit) each year or $2.39 on an earnings per share basis. Haemonetics employs 3,216 workers across the globe.View Additional Information About Haemonetics.

The official website for Haemonetics is http://www.haemonetics.com/.

Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]